2021 ASCO Virtual Meeting: Leukemia TALK - Episode 2

Phase II Results: Ponatinib + Blinatumomab in Ph+ ALL

July 8, 2021

Jorge Cortes, MD, Georgia Cancer Center, Robin Foa, MD, Sapienza University, Elias Jabbour, MD, MD Anderson Cancer Center, Doug Smith, MD, John Hopkins Medicine

Elias Jabbour, MD, highlights early findings from a phase 2 study of the combination of ponatinib and blinatumomab in Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).

EP. 1: OPTIC Primary Analysis: a Dose-Optimization Study of 3 Starting Doses of Ponatinib in CML Treatment

Now Viewing

EP. 2: Phase II Results: Ponatinib + Blinatumomab in Ph+ ALL

EP. 3: GIMEMA LAL2116, D-ALBA, Updated Results and Prognostic Impact of IKZF1 in Ph+ ALL

EP. 4: GIMEMA LALl2317: Sequential Chemotherapy and Blinatumomab for Adult ALL

EP. 5: MRD as a Prognostic Indicator in Children and Young Adults with Very High-Risk ALL

Data from the following presentations are discussed:

Combination of ponatinib and blinatumomab in Philadelphia chromosome-positive acute lymphoblastic leukemia: Early results from a phase II study. (Short, ASCO 2021 Abstract 7001)
- Efficacy: 28 patients (currently 38 at the time of this interview) with either newly diagnosed (ND) or relapsed/refractory (R/R) Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) were enrolled in the phase II study. 100% of ND patients responded to treatment compared to 88% of R/R patients. A complete molecular response was noted in 86% of enrolled patients (87% in ND vs 86% in R/R patients). A greater treatment benefit was noted in the ND cohort with an estimated 1-year overall survival (OS) and event-free survival rate of 94% and 88%, respectively. This is compared to the 88% and 55% OS and event-free survival rates noted in the R/R patient cohort.
- Safety: Treatment with ponatinib was well tolerated in both patient cohorts with only grade 1-2 side effects noted. Treatment with ponatinib was not discontinued due to toxicity in any patient.